The new laboratory will investigate how to use small molecules to control cell behavior, aiming to develop new therapeutic strategies. This approach will enable the identification of unknown biological mechanisms and open new avenues for disease treatment.
Key research areas include identifying molecules that selectively kill treatment-resistant tumor cells, modulating immune responses to combat cancer or reduce autoimmune diseases, and promoting myelin repair in conditions like multiple sclerosis.
Dr. Lairson's arrival strengthens IRB Barcelona's expertise in chemical biology and therapeutic discovery, complementing existing programs in cancer, cell signaling, and cellular plasticity. His laboratory will join the Institute's Ageing and Metabolism research program.
Dr. Lairson obtained his PhD in Chemistry from the University of British Columbia (Canada) and conducted postdoctoral research at Scripps Research. His work has been published in leading scientific journals such as Nature and Science.
